BIOANALYTICAL SYSTEMS, INC.

Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology

Retrieved on: 
Wednesday, March 17, 2021
Health sciences, Life sciences, Health, Pharmacology, Safety pharmacology, Clinical trial

Safety pharmacology evaluations are critical for assessing the impact of drug candidates.

Key Points: 
  • Safety pharmacology evaluations are critical for assessing the impact of drug candidates.
  • By summer 2021, Inotiv expects to offer integrated safety pharmacology packages that include core battery tests for cardiovascular, respiratory, and central nervous system functions as standalone safety pharmacology packages or as part of a full investigational new drug / clinical trial application program.
  • The initiative to add cardiovascular safety pharmacology began in April 2020, as we assembled our cardiovascular safety pharmacology team and conducted validation studies to fully support this new offering.
  • The Company focuses on developing innovative services supporting its clients discovery and development objectives for improved decision-making and accelerated goal attainment.

Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN

Retrieved on: 
Tuesday, March 9, 2021
Animal testing, Animal rights, Applied ethics, Animal ethics, Association for Assessment and Accreditation of Laboratory Animal Care International, Ethics, Association for Assessment and Accreditation of Laboratory Animal Care, Lafayette

In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium.

Key Points: 
  • In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium.
  • Last month, the additional West Lafayette capacity was successfully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council.
  • The Company believes this is an important step forward as it remains focused on strategic growth.
  • The West Lafayette facility showcases advanced in vivo capabilities, purpose-built to characterize pharmacologic and toxicologic parameters of drug candidates.

Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference

Retrieved on: 
Thursday, March 4, 2021
Health sciences, Contract research organizations, Pharmaceutical industry, Pharmacology, Pharmacy, Life sciences

A webcast of the presentation will be available on March 9, 2021, at 7:00 a.m.

Key Points: 
  • A webcast of the presentation will be available on March 9, 2021, at 7:00 a.m.
  • ET through a link that will be posted on theInvestorssection of the Companys website at ir.inotivco.com and will be available for approximately 90 days.
  • Bioanalytical Systems, Inc., doing business as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations.
  • The Company focuses on developing innovative services supporting its clients discovery and development objectives for improved decision-making and accelerated goal attainment.

Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Laboratory Infrastructure and Data and Study Management Technologies

Retrieved on: 
Wednesday, February 24, 2021
Information technology management, Articles, Information systems, Business process, Groupware, Workflow, Laboratory information management system, Business process management, Information technology, Automation, Information

In November 2020, Inotiv hired Todd Francisco as Director, Laboratory Information Systems, to assist with Company directives related to laboratory infrastructure and data and study management technologies.

Key Points: 
  • In November 2020, Inotiv hired Todd Francisco as Director, Laboratory Information Systems, to assist with Company directives related to laboratory infrastructure and data and study management technologies.
  • Inotiv recently partnered with Centric Consulting , LLC, a digital, business and technology solutions company, to facilitate the design and implementation of an enterprise technology solution for study management.
  • The Company believes that integrating study management activities and migrating multiple legacy systems to a new, singular platform, will improve processes, enable a more seamless, automated workflow and improve client deliverables.
  • Having one scalable, data and study management platform is fundamental to our success.

Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer

Retrieved on: 
Thursday, February 11, 2021
Beattie

WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the Company, We, Our or Inotiv), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021.

Key Points: 
  • WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the Company, We, Our or Inotiv), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021.
  • In these roles, Mr. Beattie was responsible for driving operational performance for divisions with revenue in excess of $100 million.
  • Mr Beattie also led a new business venture (Charles River Accelerator and Development Lab), and integrated an expanding Biologics Testing Solutions business.
  • Mr. Beattie held certification as Diplomate of the American Board of Toxicology (DABT) between 1999 and 2019.

Bioanalytical Systems, Inc., Announces First Quarter Fiscal 2021 Financial Results

Retrieved on: 
Tuesday, February 9, 2021

Robert Leasure, Jr., the Company's President and Chief Executive Officer, commented, We commenced fiscal 2021 with improved first quarter financial results, including 38.5% revenue growth year over year, expanding margins, positive operating income and $1.3 million of adjusted EBITDA.

Key Points: 
  • Robert Leasure, Jr., the Company's President and Chief Executive Officer, commented, We commenced fiscal 2021 with improved first quarter financial results, including 38.5% revenue growth year over year, expanding margins, positive operating income and $1.3 million of adjusted EBITDA.
  • Service segment revenue for Q1 FY 2021 increased 40.3% to $17.0 million, from $12.1 million in Q1 FY 2020.
  • Cash provided by operating activities was $1.7 million in Q1 FY 2021, compared to $1.5 million in Q1 FY 2020.
  • Management will host a conference call on Tuesday, February 9, 2021, at 4:30 pm ET to discuss Q1 FY 2021 financial results.

Bioanalytical Systems, Inc., to Report First Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, February 9, 2021

Retrieved on: 
Tuesday, January 26, 2021
Health sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Pharmaceutical sciences, Health care, Contract research organizations, Pharmaceuticals policy, Analytical chemistry, Pharmaceutical industry in China

Bioanalytical Systems, Inc., doing business as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations.

Key Points: 
  • Bioanalytical Systems, Inc., doing business as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations.
  • The Company focuses on developing innovative services supporting its clients discovery and development objectives for improved decision-making and accelerated goal attainment.
  • The Companys products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market.
  • Visit inotivco.com for more information about the Company.

Inotiv Broadens Pathology Service Offerings

Retrieved on: 
Tuesday, January 19, 2021
Clinical pathology, Anatomical pathology, Pathology

WEST LAFAYETTE, Ind., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (BASi, the Company, We, Our or Inotiv), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the most recent hiring related to the continued expansion of the Companys pathology service offerings through ongoing investment and key hires.

Key Points: 
  • WEST LAFAYETTE, Ind., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (BASi, the Company, We, Our or Inotiv), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the most recent hiring related to the continued expansion of the Companys pathology service offerings through ongoing investment and key hires.
  • Effective January 18, 2021, Adam Aulbach, DVM, DACVP, joined the Company as Director, Clinical Pathology.
  • We assess the needs of our clients on an ongoing basis and respond by enhancing our offerings, said Dr. Stewart Jacobson, Senior Vice President, Pathology.
  • The ability to provide expertise in veterinary clinical pathology, and to integrate that expertise with our already strong anatomic pathology service, should create even greater value for our clients.

Daniel Smeak, DVM, ACVS, Joins Inotiv as Vice President, Surgical Models

Retrieved on: 
Monday, January 11, 2021
Fictional characters, Darth Maul, Surgical instrument

Danis a skilled and experienced surgeon, with humble confidence and a commitment to delivering exceptional client experience that aligns with Inotivs core values, said Dr. Don Maul, Sr. Vice President, Surgical Models.

Key Points: 
  • Danis a skilled and experienced surgeon, with humble confidence and a commitment to delivering exceptional client experience that aligns with Inotivs core values, said Dr. Don Maul, Sr. Vice President, Surgical Models.
  • Danadds credibility and versatility to the surgical device services we provide our sponsors.
  • His talent is a valuable asset as our Company continues to solidify our position as a premier CRO in the United States and beyond.
  • The opportunity to work with Inotivs Fort Collins surgical team is exciting to me, said Dr. Smeak.

BASi Releases Earnings for Fourth Quarter of Fiscal 2020

Retrieved on: 
Monday, December 21, 2020
Profit, Finance, Money, Fundamental analysis, Economy, Earnings before interest, taxes, depreciation and amortization, Private equity, Net income, Income, fis

Service revenue for the fourth quarter of fiscal 2020 increased 11.1% to $14,992,000 compared to $13,493,000 for the same period in fiscal 2019.

Key Points: 
  • Service revenue for the fourth quarter of fiscal 2020 increased 11.1% to $14,992,000 compared to $13,493,000 for the same period in fiscal 2019.
  • The book-to-bill ratio for the fourth quarter of 2020 was 1.48x which resulted in a 1.26x ratio for fiscal 2020.
  • Net loss for the fourth quarter of fiscal 2020 amounted to a loss of $1,792,000, or $0.16 per diluted share, compared to net income of $290,000, or $.03 per diluted share for the fourth quarter of fiscal 2019.
  • Adjusted EBITDA for the fourth quarter of fiscal 2020 amounted to $55,000, compared to Adjusted EBITDA for the fourth quarter of fiscal 2019 of $1,330,000.